A Study of LY2510924 and Durvalumab in Participants With Solid Tumors

I2V-MC-CXAD -

The main purpose of this study is to evaluate the safety and tolerability of chemokine (C-X-C Motif) receptor 4 (CXCR4) peptide antagonist LY2510924 and durvalumab for phase 1a and 1b in participants with advanced refractory solid tumors.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
What the trial is testing?
Could I receive a Placebo?
No
Enrollment Goal
9
Trial Dates
Sep 1, 2016 - Sep 25, 2017
How long will I be in the trial?
The duration of your participation depends on how well your disease responds to the study treatment.
Trial Phase
I

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.